Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects
SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects